Cancer Immunology Research · 2021 · 144 citations · 37 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyT Cell ExhaustionT Cell Responses To TumorsTumor Immune MicroenvironmentTumor-infiltrating LymphocytesAdrenergic Receptor SignalingCd28 CostimulationChronic StressExhaustion MarkersImmune Checkpoint Inhibitor TherapyImmune Effector FunctionsStress SignalingT-cell Exhaustion Regulation
Metabolic dysfunction and exhaustion in tumor-infiltrating T cells have been linked to ineffectual antitumor immunity and the failure of immune checkpoint inhibitor therapy. We report here that chronic stress plays a previously unrecognized role in regulating the state of T cells in the tumor microenvironment (TME). Using two mouse tumor models, we found that blocking chronic adrenergic stress signaling using the pan β-blocker propranolol or by using mice lacking the β2-adrenergic receptor (β2-AR) results in reduced tumor growth rates with significantly fewer tumor-infiltrating T cells that express markers of exhaustion, with a concomitant increase in progenitor exhausted T cells. We also report that blocking β-AR signaling in mice increases glycolysis and oxidative phosphorylation in tumor-infiltrating lymphocytes (TIL), which associated with increased expression of the costimulatory molecule CD28 and increased antitumor effector functions, including increased cytokine production. Using T cells from Nur77-GFP reporter mice to monitor T-cell activation, we observed that stress-induced β-AR signaling suppresses T-cell receptor (TCR) signaling. Together, these data suggest that chronic stress-induced adrenergic receptor signaling serves as a "checkpoint" of immune responses and contributes to immunosuppression in the TME by promoting T-cell metabolic dysfunction and exhaustion. These results also support the possibility that chronic stress, which unfortunately is increased in many patients with cancer following their diagnoses, could be exerting a major negative influence on the outcome of therapies that depend upon the status of TILs and support the use of strategies to reduce stress or β-AR signaling in combination with immunotherapy.
37
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih‐Hao Chang, Jing Qiu, David O’Sullivan et al. · Cell · 2015 · 3.2K citations · Full text
Medicine, Cancer Biology, Oncology +16
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui, Jeanne Cheung, Jing Zhu et al. · Science · 2017 · 1.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping‐Chih Ho, Jessica Bihuniak, Andrew N. Macintyre et al. · Cell · 2015 · 1.4K citations · Full text